HA Concentration: 24.0 mg/mL ± 5%

Lidocaine HCl: 0.3% w/v

Cross-linking Agent: BDDE (4th-Gen)

Residual BDDE: < 2.0 ppm (Undetectable) [1]

Endotoxin Level: < 0.2 EU/mL

• Elastic Modulus (G’): Maintains structural integrity under dynamic facial movement. Sub-Q variant G’ > 400 Pa.

• Longevity: 92% volume retention observed at 12 months post-procedure [2]. Full biodegradation via hyaluronidase pathway.

• Biocompatibility: 3D matrix stabilization yields 98.7% tissue integration rate within 14 days, minimizing granuloma risk.

Kairax™ Fine

Particle Size: 200 μm

Injection Depth: Superficial Dermis

Indications: Periorbital lines, fine wrinkles

Volume: 1.0 mL

Kairax™ Deep

Particle Size: 500 μm

Injection Depth: Mid-to-Deep Dermis

Indications: Nasolabial folds, lip augmentation

Volume: 1.1 mL

Kairax™ Sub-Q

Particle Size: 1000 μm

Injection Depth: Subcutaneous / Supraperiosteal

Indications: Jawline, cheek contouring

Volume: 1.0 mL

Strictly for use by licensed medical practitioners holding formal training in facial anatomy and injection techniques.

1. Strict aseptic technique required.

2. Maximum dosage: 2.0 mL per treatment session.

3. Aspiration prior to injection is mandatory to prevent intravascular occlusion.

4. Store between 2-25°C. Do not freeze.

Absolute Contraindications: Pregnancy, lactation, known hypersensitivity to HA or gram-positive bacterial proteins, porphyria.

Adverse Events (AE): Clinical trials indicate a 12.7% incidence of localized, transient erythema/edema, resolving spontaneously within 48-72 hours [3].

Interaction: Delay treatment if the patient is on active systemic anticoagulants or high-dose NSAIDs to mitigate hematoma risk.